Core Viewpoint - The announcement indicates that the application for the transfer of the production site for Lefamulin injection, 150mg/15mL, has been approved by the FDA, which is a significant development for the company and its product line [1] Group 1: Company Developments - The subsidiary Hong Kong Jianyou has successfully submitted a New Drug Application (NDA) to the FDA for Lefamulin injection [1] - The production site for Lefamulin injection has been transferred to Jianjin Pharmaceutical Co., Ltd., and this application has received FDA approval [1] - Lefamulin injection, marketed under the brand name XENLETA, was initially approved by the FDA on August 19, 2019 [1] Group 2: Market Context - Currently, there are no approved generic versions of Lefamulin injection available in the U.S. market [1]

Investment Rating - The report maintains a "Market Perform" rating for the pharmaceutical and biotechnology industry, indicating that the industry index is expected to perform within ±10% of the market index over the next six months [28][37]. Core Insights - The SW pharmaceutical and biotechnology industry underperformed the CSI 300 index, declining by 1.91% from January 23 to February 5, 2026, which is approximately 0.74 percentage points lower than the index [12]. - Most sub-sectors within the industry recorded negative returns during the same period, with offline pharmacies and vaccine sectors showing the best performance, increasing by 3.01% and 0.12% respectively, while other sectors like biological products and chemical preparations saw declines of 3.28% and 3.27% [13]. - Approximately 34% of stocks in the industry recorded positive returns, while 66% experienced negative returns during the reporting period [14]. - The overall price-to-earnings (PE) ratio for the SW pharmaceutical and biotechnology industry was approximately 51.00 times as of February 5, 2026, indicating a decrease in industry valuation [18]. Summary by Sections 1. Market Review - The SW pharmaceutical and biotechnology industry underperformed the CSI 300 index, with a decline of 1.91% from January 23 to February 5, 2026 [12]. - Most sub-sectors recorded negative returns, with offline pharmacies and vaccines performing relatively well [13]. - About 34% of stocks in the industry had positive returns, with significant variations in individual stock performance [14]. - The industry valuation has decreased, with a PE ratio of approximately 51.00 times [18]. 2. Industry News - The 11th batch of national procurement results is set to be implemented in February, with notifications already released by 17 provinces [26]. - The National Medical Insurance Administration has issued a notice to accelerate the cultivation and opening of application scenarios in the medical insurance field [25]. 3. Company Announcements - Jianyou Co., Ltd. announced that its subsidiary received FDA approval for its product, sodium selenite injection [27]. 4. Industry Outlook - The report suggests a focus on investment opportunities in the brain-computer interface sector as part of the 14th Five-Year Plan, with ongoing policy support [28]. - Recommended sectors for investment include medical devices, pharmaceutical commerce, aesthetic medicine, scientific services, hospital and diagnostic services, traditional Chinese medicine, innovative drugs, biological products, and CXO services [29].

Core Viewpoint - The Ministry of Industry and Information Technology (MIIT) has released a public list of green factories and green industrial parks for the year 2025, highlighting the importance of sustainable development in the manufacturing sector [2]. Group 1: Green Factories and Industrial Parks - The list includes newly cultivated green factories and industrial parks, as well as those undergoing dynamic management adjustments, which were recommended by provincial industrial and information departments and reviewed by experts [4]. - Notable companies included in the list are Beijing Haibo Sichuang Technology Co., Ltd., Envision Energy Technology (Jiangsu) Co., Ltd., and Honeycomb Energy Technology Co., Ltd. [3][4]. Group 2: Contact Information and Public Notice - The public notice period for the list is from February 5, 2026, to February 19, 2026, during which any objections can be submitted to the MIIT [5]. - The contact unit for inquiries is the Energy Conservation and Comprehensive Utilization Department of the MIIT, with a provided contact number for further communication [5].

南京健友生化制药股份有限公司 | 证券代码：603707 | 证券简称：健友股份 | 公告编号：2026-006 | | --- | --- | --- | | 债券代码：113579 | 债券简称：健友转债 | | 二、药品其他相关情况 关于子公司产品亚硒酸注射液获得美国 FDA 批准的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 南京健友生化制药股份有限公司（以下简称"健友股份"或"公司"）子公 司健进制药有限公司（以下简称"健进制药"）于近日收到美国食品药品监督管 理局（以下简称"美国 FDA"）签发的亚硒酸注射液（600 mcg/10 mL）的 ANDA 批准通知（ANDA 号：219472）。现将相关情况公告如下： 一、药品的基本情况 （一）药品名称：亚硒酸注射液 （二）适 应 症：适用于需要肠外营养的成人与儿科患者，作为肠外营养液 中硒的来源，用于当口服或肠内营养无法实施、不足或存在禁忌时。 （三）剂 型：注射剂 （四）规 格：600 mcg/10 mL （五）ANDA 号：219472 （六）申 请 ...

Core Viewpoint - The company, Jianyou Co., Ltd. (603707.SH), announced that its subsidiary, Jianjin Pharmaceutical Co., Ltd., has received ANDA approval from the U.S. FDA for its selenium injection (600mcg/10mL) [1] Group 1 - The approved product is indicated for adult and pediatric patients requiring parenteral nutrition, serving as a source of selenium in parenteral nutrition solutions [1] - The approval is significant for patients who cannot implement, have insufficient, or have contraindications for oral or enteral nutrition [1]

Core Viewpoint - The company Jianyou Co., Ltd. has received ANDA approval from the U.S. FDA for its injectable sodium selenite solution, indicating a significant milestone for the company in expanding its product offerings in the parenteral nutrition market [1] Group 1 - Jianyou's subsidiary, Jianjin Pharmaceutical Co., Ltd., has been granted ANDA approval for sodium selenite injection (600mcg/10mL) [1] - The approved indication is for use in adult and pediatric patients requiring parenteral nutrition, serving as a source of selenium when oral or enteral nutrition is not feasible, insufficient, or contraindicated [1]

Core Viewpoint - The company announced that its subsidiary, Jianjin Pharmaceutical Co., Ltd., has received ANDA approval from the U.S. FDA for sodium selenite injection (600 mcg/10 mL), which is expected to positively impact the company's operating performance [1] Group 1: Product Approval - The approved drug is indicated for adult and pediatric patients requiring parenteral nutrition, serving as a source of selenium when oral or enteral nutrition is not feasible, insufficient, or contraindicated [1] - Currently, there are five approved generic versions of sodium selenite injection available in the U.S. market [1] Group 2: Financial Investment - The company has invested approximately RMB 6.5605 million in the research and development of this project [1]

证券日报网讯2月2日，健友股份（603707）发布公告称，截至2026年1月31日，公司通过上海证券交易 所交易系统以集中竞价交易方式已累计回购股份137.9995万股，已累计回购股份占公司总股本的比例为 0.09%，成交最低价为9.56元/股，成交最高价为11.66元/股，支付的总金额为人民币1，500.85万元(不含 交易费用及印花税)。 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 债券代码：113579 债券简称：健友转债 南京健友生化制药股份有限公司 证券代码：603707 证券简称：健友股份 公告编号：2026-005 关于股份回购进展的公告 上述回购股份符合法律法规及公司回购股份方案的规定。 三、其他事项 公司将严格按照《上市公司股份回购规则》《上海证券交易所上市公司自律 监管指引第 7 号——回购股份》等相关规定，在回购期限内根据市场情况择机做出 回购决策并予以实施，同时根据回购股份事项进展情况及时履行信息披露义务， 敬请广大投资者注意投资风险。 | 回购方案首次披露日 | 2025/4/29，由董事长唐咏群先生提议 | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 年 月 2025 5 5 | 20 | 日~2026 | 年 | 月 | 日 19 | | 预计回购金额 | 2,000万元~4,000万元 | | | | | | | 回购用途 | ...

Group 1 - The company, Jianyou Co., Ltd. (603707.SH), has announced a share buyback program, having repurchased a total of 1.379995 million shares as of January 31, 2026 [1] - The repurchased shares account for 0.09% of the company's total share capital [1] - The total amount paid for the buyback is approximately RMB 15.0085 million, excluding transaction fees and stamp duty [1] Group 2 - The minimum transaction price for the repurchased shares was RMB 9.56 per share, while the maximum price reached RMB 11.66 per share [1]